Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830477 · ClinicalTrials.gov registry record
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 313
- Enrollment target
NCT02830477: Completed study, sponsored by Bayer.
NCT02830477 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 313 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02830477 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 313 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose \& dosing frequency, reason for choice of treatment regimen, FVIII product switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data (if performed), KOVALTRY consumption, as well as safety data.
Interventions
- BIOLOGICAL Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2021-03-01 |
What the finished NCT02830477 record still lists
NCT02830477 is an observational study that tracks outcomes without assigning an intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 is the first listed.
NCT02830477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02830477 about?
NCT02830477 is a clinical study titled "Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis". The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose \& dosing frequency, reason for choice of treatment regimen, FVIII prod...
What is the current status of trial NCT02830477?
This trial is currently completed. The enrollment target is 313 participants. The study started on 2016-10-14. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT02830477?
The interventions under investigation include: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02830477?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI